Communications Biology (Jan 2021)
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
- Domenico Albino,
- Martina Falcione,
- Valeria Uboldi,
- Dada Oluwaseyi Temilola,
- Giada Sandrini,
- Jessica Merulla,
- Gianluca Civenni,
- Aleksandra Kokanovic,
- Alessandra Stürchler,
- Dheeraj Shinde,
- Mariangela Garofalo,
- Ricardo Pereira Mestre,
- Vera Constâncio,
- Martha Wium,
- Jacopo Burrello,
- Nicolò Baranzini,
- Annalisa Grimaldi,
- Jean-Philippe Theurillat,
- Daniela Bossi,
- Lucio Barile,
- Rui M. Henrique,
- Carmen Jeronimo,
- Luiz Fernando Zerbini,
- Carlo V. Catapano,
- Giuseppina M. Carbone
Affiliations
- Domenico Albino
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Martina Falcione
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Valeria Uboldi
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Dada Oluwaseyi Temilola
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa and Integrative Biomedical Sciences Division, Faculty of Health Sciences, University of Cape Town
- Giada Sandrini
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Jessica Merulla
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Gianluca Civenni
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Aleksandra Kokanovic
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Alessandra Stürchler
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Dheeraj Shinde
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Mariangela Garofalo
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua
- Ricardo Pereira Mestre
- Medical Oncology, Oncology Institute of Southern Switzerland
- Vera Constâncio
- Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)
- Martha Wium
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa and Integrative Biomedical Sciences Division, Faculty of Health Sciences, University of Cape Town
- Jacopo Burrello
- Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Foundation, USI
- Nicolò Baranzini
- Department of Biotechnology and Life Science, Università degli Studi dell’Insubria
- Annalisa Grimaldi
- Department of Biotechnology and Life Science, Università degli Studi dell’Insubria
- Jean-Philippe Theurillat
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Daniela Bossi
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Lucio Barile
- Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Foundation, USI
- Rui M. Henrique
- Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)
- Carmen Jeronimo
- Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)
- Luiz Fernando Zerbini
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa and Integrative Biomedical Sciences Division, Faculty of Health Sciences, University of Cape Town
- Carlo V. Catapano
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- Giuseppina M. Carbone
- Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI)
- DOI
- https://doi.org/10.1038/s42003-020-01642-5
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 13
Abstract
Following on reports that miR-424 expression promotes oncogenesis, Domenico Albino et al. find that extracellular vesicles (EVs) in the plasma of prostate cancer patients secrete miR-424. Using cell-based and animal models, they demonstrate that EV-mediated release of miR-424 can transfer oncogenic signals across cells to promote recurrence and metastatic progression.
